Understanding Medication-Assisted Treatment (MAT): Access, Evidence & Finding Providers

Q: What is medication-assisted treatment (MAT)?

Medication-assisted treatment combines FDA-approved medications, methadone, buprenorphine (Suboxone), or naltrexone (Vivitrol) - with counseling and behavioral therapies to treat substance use disorders, primarily opioid use disorder. MAT is considered the gold standard for opioid addiction treatment. Research consistently shows it reduces opioid use, overdose deaths, criminal activity, and infectious disease transmission while improving treatment retention.

Q: How many treatment facilities offer MAT?

In the SAMHSA N-SUMHSS record this directory is built on, 8,487 of 17,974 treatment facilities (47%) report offering some form of medication-assisted treatment. Availability varies widely by state and city, rural areas have markedly fewer MAT providers. PlainRecovery shows which facilities report MAT in every city and state.

Q: What is the difference between methadone and buprenorphine?

Both reduce cravings and withdrawal symptoms for opioid use disorder, but they work differently and are regulated differently. Methadone is a full opioid agonist that must be dispensed daily at a certified Opioid Treatment Program (OTP) - patients cannot take it home initially. Buprenorphine is a partial agonist that can be prescribed by any licensed prescriber and taken at home, making it more accessible. Both are effective; the choice depends on individual clinical needs, treatment history, and local availability.

Q: Does insurance cover medication-assisted treatment?

Most insurance plans are required to cover MAT under the Mental Health Parity and Addiction Equity Act and the Affordable Care Act. Medicaid covers MAT in all states, though specific medications and program requirements vary by state. Medicare covers buprenorphine and naltrexone. Many MAT providers also accept sliding-fee scales for uninsured patients. PlainRecovery shows which facilities accept Medicaid, Medicare, and offer sliding-fee arrangements.

Why MAT access matters

Opioid use disorder is a medical condition, and like other chronic conditions, it responds best to evidence-based treatment. The evidence for medication-assisted treatment is among the strongest in addiction medicine, meta-analyses consistently show that MAT reduces all-cause mortality, opioid use, overdose deaths, and transmission of infectious diseases like HIV and hepatitis C.

Yet access to MAT remains uneven. Regulatory barriers, provider shortages, stigma within the treatment community, and geographic gaps mean that many people seeking treatment cannot access MAT even when it would be the most effective option. PlainRecovery's state pages and facility rankings show where these gaps exist.

The three FDA-approved MAT medications

Methadone is a full opioid agonist, it activates the same brain receptors as opioids but in a controlled, steady manner that eliminates withdrawal symptoms and reduces cravings without producing the euphoria of misused opioids. Methadone must be dispensed at a certified Opioid Treatment Program (OTP), which requires daily visits initially. It has the longest clinical track record of any MAT medication, and suits patients with severe opioid use disorder who benefit from the structure of daily clinic visits, though those daily visits are a real barrier for people with jobs, childcare, or limited transportation, and rural areas may have no OTP within driving distance.

Buprenorphine (Suboxone, Sublocade) is a partial opioid agonist. It can be prescribed by any licensed prescriber and taken at home, making it far more accessible than methadone. The 2023 elimination of the DATA-waiver ("X-waiver") requirement means any DEA-registered prescriber can now prescribe buprenorphine.

Naltrexone (Vivitrol) is an opioid antagonist, it blocks opioid receptors entirely. It does not reduce withdrawal symptoms and requires full detoxification before starting. Available as a monthly injection (Vivitrol) or a daily tablet, it removes the diversion concern associated with agonist medications but requires higher patient motivation.

The three FDA-approved medications for opioid use disorder compared by mechanism and how they are dispensed.
Medication	Mechanism	How dispensed	Best suited for
Methadone	Full agonist	Daily visits at a certified OTP	Severe OUD; patients who benefit from daily structure
Buprenorphine (Suboxone)	Partial agonist	Prescribed by any DEA-registered prescriber; taken at home	Most patients; rural and work-constrained access
Naltrexone (Vivitrol)	Antagonist	Monthly injection or daily oral tablet	Patients past detox who prefer a non-opioid option

Finding MAT providers near you

Step 1, Search by city or state. Use PlainRecovery's state pages or city pages to find facilities near you, then filter for facilities that report MAT.

Step 2, Check which medications are available. Not every MAT facility offers all three medications. Some offer only buprenorphine; OTPs provide methadone. The SAMHSA survey records whether a facility reports MAT, but not always which specific medication, so confirm by phone.

Step 3, Verify insurance acceptance. Check whether the facility accepts your insurance, Medicaid, Medicare, or offers a sliding-fee scale. 15,045 of the listed facilities (84%) report accepting Medicaid and 6,631 (37%) report sliding-fee pricing.

Step 4, Call to verify. Facility details come from SAMHSA's annual survey and may not reflect current availability. Always call to confirm the facility is accepting new patients, offers the specific medication you need, and accepts your payment method.

Frequently asked questions

What is medication-assisted treatment (MAT)?

MAT combines FDA-approved medications, methadone, buprenorphine, or naltrexone, with counseling and behavioral therapies. It is considered the gold standard for opioid addiction treatment and reduces overdose deaths and all-cause mortality.

How many treatment facilities offer MAT?

In this directory, 8,487 of 17,974 facilities (47%) report offering some form of MAT. Availability varies sharply by location, rural areas have the biggest gaps.

What is the difference between methadone and buprenorphine?

Methadone is a full agonist requiring daily clinic visits (OTP). Buprenorphine is a partial agonist that can be prescribed by any licensed prescriber and taken at home. Both are effective; the choice depends on clinical needs and local availability.

Does insurance cover medication-assisted treatment?

Most plans are required to cover MAT under parity laws and the ACA. Medicaid covers MAT in all states. Medicare covers buprenorphine and naltrexone. Many providers also offer sliding-fee scales.

Sources

SAMHSA - N-SUMHSS (National Substance Use and Mental Health Services Survey)
SAMHSA - FindTreatment.gov
SAMHSA, National Helpline: 1-800-662-4357

All facility figures on this page are counts from the SAMHSA N-SUMHSS record powering this directory, computed live at request time.

The MAT figures here are drawn from the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA). According to its National Substance Use and Mental Health Services Survey (N-SUMHSS), the federal record catalogs more than 17,000 substance-use and mental-health treatment facilities nationwide. This directory was last rebuilt from that survey in May 2026, see our methodology for how the data is collected and updated. Always confirm details directly with a facility before relying on them.

Every figure on PlainRecovery is rendered directly from SAMHSA's published N-SUMHSS facility data, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these facility listings, or report a data error. Data current as of 2024 N-SUMHSS release.